ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 2376

Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis

Zoe Brown 1, Robert Metcalf 2, Jana Bednarz 3, Christiana Stavrou 4, Llewellyn Spargo 2, Michael James 2 and Susanna Proudman5, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, 3Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, 4University College London Hospital, London, United Kingdom, 5University of Adelaide, Adelaide, Australia

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Early Rheumatoid Arthritis, modifiable risk, obesity, rheumatoid arthritis, treatment and tobacco use

Session Information

Date: Tuesday, November 12, 2019

Title: RA – Treatments Poster III: Safety and Outcomes

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated examination of these lifestyle factors as predictors of RA outcomes was undertaken in a single early RA cohort receiving standardised algorithm-directed treat-to-target DMARD therapy.

Methods: Consecutive patients attending the Early Arthritis Clinic at the Royal Adelaide Hospital with recent-onset RA according to the 1987 revised American College of Rheumatology criteria and with disease duration < 12 months were eligible. All patients commenced ‘triple therapy’ with methotrexate, sulfasalazine and hydroxychloroquine and received advice to take fish oil supplements at anti-inflammatory doses, except for 139 patients within this cohort of 339 who participated in a randomised placebo controlled trial (RCT) of fish oil supplementation. Prognostic variables for DAS28 remission and DAS28 low disease activity (LDA) at the 12 month visit (+/- 6 weeks window was allowed) were identified using multivariable logistic regression models, correcting for potential confounders (age, sex, RF and CCP status and shared epitope). Omega-3 status was assessed as plasma eicosapentaenoic acid (EPA) levels.

Results: Of 311 participants with complete data, 57.6% reached DAS28 LDA and 43.7% were in DAS28 remission at one year. Increase in plasma EPA was associated with an increase in the odds of being in DAS28 LDA (OR=1.28; p< 0.0001) and DAS28 remission (OR=1.22; p< 0.001). There was a statistically significant interaction between smoking status and BMI on DAS28 LDA. Increase in BMI was associated with a decrease in the odds of being in DAS28 LDA in current and former smokers, but had no impact on LDA in patients who had never smoked. There were no statistically significant associations with BMI or smoking history and DAS28 remission. While a 1kg/m2 increase in BMI was associated with a decrease in the odds of having DAS28 low disease activity at 1 year in current and former smokers, it had no impact in patients who had never smoked.

Conclusion: Among all prognostic factors, fish oil supplementation in early RA patients receiving T2T therapy is significantly associated with the greatest increased odds of achieving DAS28 LDA at one year. The effect modification by smoking status on the association of BMI with treatment outcomes in early RA strongly supports counselling for lifestyle modification in patients who have a smoking history, particularly if they are overweight.


Table 1

Table 1. Odds of DAS28 Low Disease Activity at 1 year after commencing treatment


Disclosure: Z. Brown, None; R. Metcalf, None; J. Bednarz, None; C. Stavrou, None; L. Spargo, None; M. James, Melrose Health, 9; S. Proudman, Actelion, 2, Boehringer-Ingelheim, 2, 6, Bayer, 2, Corbus, 2, Melrose Health, 9.

To cite this abstract in AMA style:

Brown Z, Metcalf R, Bednarz J, Stavrou C, Spargo L, James M, Proudman S. Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/modifiable-factors-associated-with-response-to-treatment-in-early-rheumatoid-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modifiable-factors-associated-with-response-to-treatment-in-early-rheumatoid-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology